Table 1.
Patient Characteristics at the Start of Combination Antiretroviral Therapy
| No. of Patients | % | |
|---|---|---|
| Total | 1255 | 100.0 |
| Sex | ||
| Male | 886 | 70.6 |
| Female | 369 | 29.4 |
| Ethinicity | ||
| Chinese | 527 | 42.0 |
| Indian | 193 | 15.4 |
| Thai | 310 | 24.7 |
| Other | 225 | 17.9 |
| Mode of infection | ||
| Heterosexual | 1,013 | 80.7 |
| Homosexual | 125 | 10.0 |
| IDU only | 27 | 2.2 |
| Other | 90 | 7.2 |
| Prior AIDS illness | ||
| No | 617 | 49.2 |
| Yes | 638 | 50.8 |
| Year of cART start | ||
| ≤2000 | 264 | 21.0 |
| >2000 | 991 | 79.0 |
| HBsAg | ||
| Negative | 660 | 52.6 |
| Positive | 102 | 8.1 |
| Not tested | 493 | 39.3 |
| HCV antibody | ||
| Negative | 641 | 51.1 |
| Positive | 70 | 5.6 |
| Not tested | 544 | 43.4 |
| Median age, y (IQR) | 36 (31–42) | |
| Median CD4 count, cells/mm3 (IQR) | 63 (25–130) | |
| Median BMI,a kg/m2 (IQR) | 19.9 (17.8–22.1) | |
| Median hemoglobinears,a mg/dL (IQR) | 120 (106–133) | |
Abbreviations: IDU, intravenous drug use; cART, combination antiretroviral therapy; HbSAg, Hepatitis B surface antigen; HCV, hepatitis C virus; IQR, interquartile range; BMI, body mass index.
a
Number of patients (%) missing body mass index and hemoglobin measurements at baseline: 610 (48.6%) and 256 (20.4%), respectively.